Abstracts tagged "interleukins (IL)"

Abstract Number: 888 • 2012 ACR/ARHP Annual Meeting
Plasma Cells Express the Novel Cytokine Interleukin-36α in Psoriatic and Rheumatoid Arthritis Synovium
Anja Derer¹, Silke Frey², Maria-Elena Messbacher², Serena Bugatti³, Dominique L. Baeten⁴, Carlomaurizio Montecucco⁵, Georg A. Schett¹ and Axel J. Hueber⁶, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Internal Medicine 3, University of Erlangen, Erlangen, Germany, ³Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Division of Rheumatology, University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁶Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: IL-36α is a recent described IL-1 cytokine family member with proinflammatory and clear pathogenic properties in psoriasis. Aim of this study was to determine…
Abstract Number: 1674 • 2012 ACR/ARHP Annual Meeting
Myeloid Related Proteins Induce Muscle Derived Inflammatory Mediators in Juvenile Dermatomyositis
Kiran Nistala¹, Hemlata Varsani², Helmut Wittkowski³, Thomas Vogl⁴, Petra Krol⁵, Vanita Shah², Kamel Mamchaoui⁶, Paul Brogan², Johannes Roth⁷ and Lucy R. Wedderburn², ¹Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy, ²Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ³Muenster, Germany, ⁴Institute of Immunology, University of Muenster, Muenster, Germany, ⁵Rheumatology Unit, Department of Paediatrics and Adolescent Medicine, Prague, Czech Republic, ⁶Institut de Myologie, Paris, France, ⁷Immunology, Institute of Immunology University of Muenster, Muenster, Germany
Background/Purpose: The etiopathogenesis of Juvenile Dermatomyositis (JDM) remains poorly understood. In particular the contribution of monocytes or macrophages, which are frequently observed to be an…
Abstract Number: 813 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Prophylaxis in Patients with Chronic Kidney Disease: Analysis of 3 Clinical Trials
Robert Terkeltaub¹, Robert R. Evans², Steven P. Weinstein³, Richard Wu⁴ and H. Ralph Schumacher⁵, ¹Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ²Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁴BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: Gout flare (GF) prophylaxis in patients (pts) with chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR]
Abstract Number: 1632 • 2012 ACR/ARHP Annual Meeting
Arhalofenate Is a Novel Dual-Acting Agent with Uricosuric and Anti-Inflammatory Properties
Yun-Jung Choi, Vanina Larroca, Annette Lucman, Vic Vicena, Noe Abarca, Tim Rantz, Brian E. Lavan and Charles A. McWherter, Biology, Metabolex, Inc., Hayward, CA
Background/Purpose: In most patients with gout, elevated serum urate is linked to excess uric acid reabsoprtion in the proximal renal tubule by anion transporters/exchangers, including…
Abstract Number: 600 • 2012 ACR/ARHP Annual Meeting
Regulatory T Cells in Spondyloarthritis (SpA) Animal Model and Modulatory Role of Inducible Costimulator (ICOS)
Luiza Krause¹, Ingrid Fert¹, Karine Labroquère², Muriel Andrieu², Gilles Chiocchia³ and Maxime A. Breban⁴, ¹Immunology and Hematology Department, Institut Cochin - INSERM U1016 - CNRS (UMR 8104)-Université Paris Descartes (UMR-S 1016), Paris, France, ²Cochin Immunobiology Facility, Paris, France, ³Versailles Saint Quentin en Yvelines University, INSERM U987, UFR des Sciences de la Santé, Montigny-le-Bretonneux, France, ⁴Rheumatology Division, Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France
Background/Purpose: HLA-B27/human β2m transgenic rats (B27-rats), a model of SpA develop spontaneous colitis and arthritis. It was recently shown in this model that IL-17 producing…
Abstract Number: 1492 • 2012 ACR/ARHP Annual Meeting
IL-13 Receptors and Signaling in the Dermal Fibroblasts From Patients with Systemic Sclerosis
Yuko Ota¹, Yasushi Kawaguchi¹, Atsushi Kitani², Kae Takagi¹, Hisae Ichida¹, Yasuhiro Katsumata¹, Takahisa Gono¹, Masanori Hanaoka¹, Yuko Okamoto¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Mucosal Immunity Section, NIAID/NIH, Bethesda, MD
Background/Purpose: Interleukin (IL)-13 is a pleiotropic cytokine involved in T helper type 2 cell immune response and in the development of fibrotic conditions such as…
Abstract Number: 434 • 2012 ACR/ARHP Annual Meeting
IL-22 Mediated Pannus Formation in Autoimmune Arthritis Is PI3K/Akt/mTOR Dependent
Siba P. Raychaudhuri¹, Anupam Mitra¹, Ananya Datta Mitra², Christine Abria² and Smriti K. Raychaudhuri², ¹Rheumatology, VA Sacramento Medical CenterUC Davis School of Medicine, Mather, CA, ²Rheumatology, VA Sacramento Medical Center, Mather, CA
Background/Purpose: IL-22, a Th17 cytokine plays a key role in the formation of “pannus” in autoimmune arthritis such as rheumatoid arthritis (RA) and psoriatic arthritis…
Abstract Number: 1337 • 2012 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Pharmacokinetic Profile and Its Relationship to Changes in Pharmacodynamic Markers in Patients with Rheumatoid Arthritis
Pavel Belomestnov¹, Jennifer Hamilton², A. Thomas DiCioccio¹, Martine Jasson³ and Allen R. Radin⁴, ¹Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Predictive Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Clinical Development, Sanofi-Aventis, Paris, France, ⁴Translational Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, NY
Background/Purpose: Sarilumab, a fully human monoclonal antibody targeting interleukin-6 receptor alpha (IL-6Rα), is being evaluated for the treatment of rheumatoid arthritis (RA) based on the…
Abstract Number: 429 • 2012 ACR/ARHP Annual Meeting
The Significance of the Apoptosis Level and the Apoptosis Related Signal Proteins of CD4⁺t�ACD4⁺Foxp3⁺t Cell in Patients with Rheumatoid Arthritis
Ning Li¹, Tianrui Ma², Jie Han¹, Jieru Zhou¹ and Songguo Zheng³, ¹Rheumatology, Shanghai East Hospital, Shanghai, China, ²Rheumatology, Ningbo Pediatric Hospital, Ningbo, China, ³Division of Rheumatology and Immunology, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA
Background/Purpose: To investigate the apoptosis of CD4+T cell and Tregs in the pathogenesis and disease activity of rheumatoid arthritis patients. Methods: Isolated lymphocytes from human…
Abstract Number: 1320 • 2012 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Mark C. Genovese¹, Roy Fleischmann², Martine Jasson³, Allen R. Radin⁴, Jennifer Hamilton⁵ and Tom W.J. Huizinga⁶, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ³Clinical Development, Sanofi-Aventis, Paris, France, ⁴Translational Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁵Predictive Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anemia of chronic disease, a common extra-articular manifestation of rheumatoid arthritis (RA), which has a substantial impact on patient function, is driven in part…
Abstract Number: 332 • 2012 ACR/ARHP Annual Meeting
Blockade of CTGF Restores Aberrant Ostoclastgenesis in Collagen Induced Arthritis (CIA) Mice Through Inhibition of Th-17 Differentiation
Kazuhisa Nozawa¹, Maki Fujishiro², Ayako Yamaguchi¹, Mikiko Kawasaki², Shouzou Ichinose², Mitsuaki Yanagida², Kazuhisa Iwabuchi², Keigo Ikeda³, Shinji Morimoto⁴, Megumi Morioka⁵, Yoshinari Takasaki⁶ and Iwao Sekigawa³, ¹Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, ³Internal Medicine 2, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, ⁴Juntendo University Urayasu Hospital, Tokyo, Japan, ⁵Nihon Nosan Corporation, Nihon Nosan Corporation, Kanagawa, Japan, ⁶Internal Medicine and Rheumatology,, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Our previous study demonstrated changes in the profiles of serum protein biomarkers in infliximab-treated rheumatoid arthritis (RA) patients using a novel approach to proteomic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].